Clinical trials: Renin Angiotensin Aldosterone System
Atrial Fibrillation
Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)
Atrial fibrillation (AF) is the most prevalent, sustained type of irregular heartbeat and affects over 2 million Americans. Post-operative AF, which leads to significant morbidity and a prolonged hospital stay, complicates 20% to…
- Trial name
- NCT00141778
- Testing
- Ramipril, Spironolactone
- Where
- United States
- Volunteers
- 455 people
- Sponsor
- Vanderbilt University
Renin-Angiotensin System
The Effect of RAAS Blockers on ACE2 Levels
Blockage of renin-angiotensin-aldosterone system (RAAS) by angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) is considered the first-choice of drugs for treatment of hypertension, heart…
- Trial name
- NCT05418361
- Testing
- ACE inhibitor ,angiotensin receptor blockers
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
COVID-19, SARS-CoV2 Infection
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT05593770)
- Testing
- Fostamatinib
- Where
- 21 sites in Brazil, Germany and 3 more
- Volunteers
- 28 people
- Sponsor
- NEAT ID Foundation
Kidney, Polycystic
HALT Progression of Polycystic Kidney Disease Study B
The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two…
- Trial name
- HALT PKD B (NCT01885559)
- Testing
- Lisinopril, Telmisartan
- Where
- 7 sites in United States
- Volunteers
- 486 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Tetralogy of Fallot, Heart Defects, Congenital
Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
Rationale: The prevalence of adult patients with congenital heart disease (CHD) has steadily increased over the last decades, due to the advances in cardiac surgery.
- Conditions
- Tetralogy of Fallot, Heart Defects, Congenital, Ventricular Dysfunction, Right
- Trial name
- Redefine (NCT02010905)
- Testing
- Losartan
- Where
- 6 sites in Netherlands
- Volunteers
- 120 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy
Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose…
- Conditions
- Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria
- Trial name
- NCT00961207
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cook County Health
Type 1 Diabetes Mellitus
The Effect of Uric Acid Lowering in Type 1 Diabetes
Patients with type 1 diabetes mellitus (T1DM) are at high risk of developing kidney complications potentially leading to end stage renal disease.
- Trial name
- NCT02344602
- Testing
- Febuxostat
- Where
- Canada
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Kidney, Polycystic
HALT Progression of Polycystic Kidney Disease Study A
The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the progression of cystic disease and on the decline in renal function in autosomal dominant kidney disease (ADPKD) will be assessed in two…
- Trial name
- HALT PKD A (NCT00283686)
- Testing
- Lisinopril, Telmisartan, Standard Blood Pressure Control
- Where
- 7 sites in United States
- Volunteers
- 558 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Congestive Heart Failure, Low Cardiac Output
Losartan in Decompensated Heart Failure
The dual blockade of the renin-angiotensin-aldosterone system with an angiotensin-converting enzyme inhibitor and an angiotensin-receptor blocker used together in heart failure patients has been demonstrated to be beneficial.
- Trial name
- NCT01857999
- Testing
- Losartan
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- InCor Heart Institute
Metabolic Syndrome
Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism
Aim 1.Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone system impairs glycemic control via effects on insulin sensitivity and insulin secretion. Aim 2.
- Trial name
- NCT02034435
- Testing
- Low Sodium diet plus Salt tablet, Epleronone, Amlodipine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Vanderbilt University Medical Center
Obesity
Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
The purpose of the study is to determine if giving isosorbide,a drug that is used to treat chest pain, affects blood vessel release of an anti-clotting factor.
- Trial name
- NCT00685945
- Testing
- Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University
Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma
Ipsilateral and Contralateral Index for the Interpretation of Adrenal Vein Sampling (AVS) in Primary Aldosteronism
Adrenal vein sampling (AVS) is currently considered the gold standard for subtype diagnosis of primary aldosteronism (PA). However, the percentage of unsuitable procedures due to the unsuccessful cannulation of one of the two…
- Conditions
- Primary Aldosteronism, Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
- Trial name
- NCT04378387
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Turin, Italy
Myocardial Infarction
Effect of Renin Angiotensin Aldosterone System Genetic Polymorphism on the Pharmacological Effect of Mineralocorticoid Receptor Antagonists in Patients With Myocardial Infarction
Early treatment of Myocardial Infarction patients with mineralocorticoid receptor antagonist with help reduces the incidence of cardiac remodeling and development into heart failure.
- Trial name
- NCT05873400
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Ain Shams University
Renin-Angiotensin Aldosterone System (RAS)
Human Intestinal Amino Acid Absorption and the Role of a Local RAS
This study is to find out what role a local intestinal RAS (renin angiotensin system) plays in the context of amino acid absorption in the human intestinal tract and how this RAS and thus the amino acid absorption is influenced…
- Trial name
- NCT04524494
- Testing
- biopsy of intestinal tissue, blood draw, urine collection
- Where
- 2 sites in Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital Basel
COVID-19, SARS-CoV-2 Infection
Novel Experimental COVID-19 Therapies Affecting Host Response
The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Coronavirus Infection
- Trial name
- NECTAR (NCT04924660)
- Testing
- TXA127, TRV027, Fostamatinib
- Where
- 51 sites in United States
- Volunteers
- 1,060 people
- Sponsor
- Sean Collins
Acute Decompensated Heart Failure
RAAS Optimization for Acute CHF Patients
Holding ACEI/ARBs during initial 72 hours of admission with acute decompensated heart failure may help preserve renal function with a lesser decline in GFR.
- Trial name
- ROAD-HF (NCT03695120)
- Testing
- Change of treatment plan
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Arrhythmogenic Right Ventricular Dysplasia
Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV).
- Trial name
- BRAVE (NCT03593317)
- Testing
- Spironolactone
- Where
- 13 sites in France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Hyperkalaemia, Heart Failure with Reduced Ejection Fraction
Hyperkalaemia and Its Impact on Therapy with RAASi
Renin-angiotensin-aldosterone system inhibitors (RAASi) have transformed prognosis of patients with heart failure with reduced ejection fraction, diabetic nephropathy and chronic kidney disease.
- Conditions
- Hyperkalaemia, Heart Failure with Reduced Ejection Fraction, Left Ventricular Systolic Dysfunction
- Trial name
- REVIEW (NCT04249648)
- Where
- United Kingdom
- Volunteers
- 651 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Covid 19
Diagnosis of Endocrine Dysfunctions in Covid-19
As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells.
- Trial name
- Dyhor-19 (NCT04587375)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Montpellier